TriSalus Life Sciences (TLSIW) Short term Debt (2022 - 2023)
TriSalus Life Sciences posted quarterly Short term Debt of $10.0 million for Q2 2023, up 115.88% on a QoQ basis from $4.7 million in Q1 2023.
TriSalus Life Sciences (TLSIW) has 2 years of Short term Debt data on file, last reported at $10.0 million in Q2 2023.
- For the quarter ending Q2 2023, Short term Debt changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2023 stood at $10.0 million (changed N/A YoY), and the FY2022 full-year result was $2.5 million, changed N/A from the prior year.
- Short term Debt for Q2 2023 stood at $10.0 million, up from $4.7 million in the prior quarter.
- Across five years, Short term Debt topped out at $10.0 million in Q2 2023 and bottomed at $2.5 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | TriSalus Life Sciences | - | - | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.05 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Dec 31, 2022 | 2.45 Mn |